Skip to main content
SpringerLink
Log in

Bacterial Topoisomerase Inhibitors: Quinolones and Beyond

  • Chapter
  • First Online:
Antimicrobials

  • 3027 Accesses

Abstract

Previous studies have established the essentiality of the bacterial DNA replication process and its requisite enzymes including DNA gyrase and topoisomerase IV. The quinolone class of antibiotics provided a clinical validation of these targets and has been widely used over the past 50 years. A number of more recent examples of these compounds are described herein. Two related, but structurally distinct quinolone-like compounds are also discussed. Non-quinolones, designated novel bacterial type II topoisomerase inhibitors (NBTIs), have been explored and several examples are provided in this work. Successful development of these latter compounds could enhance and extend the clinical utility of bacterial topoisomerase inhibitors beyond the clinically valuable and commercially successful quinolone antibiotics. Bacterial topoisomerase inhibitors should continue to play an important role in the battle against bacterial pathogens for many years to come.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009) In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53:4915–4920

    Article  PubMed  CAS  Google Scholar 

  • Almer LS, Hoffrage JB, Keller EJ, Flamm RK, Shortridge VD (2004) In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 48:2771–2777

    Article  PubMed  CAS  Google Scholar 

  • Anderle C, Stieger M, Burrell M, Reinelt S, Maxwell A, Page M, Heide L (2008) Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 52:1982–1990

    Article  PubMed  CAS  Google Scholar 

  • Angehrn P, Goetschi E, Gmuender H et al (2011) A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold synthesis and antibacterial properties. J Med Chem 54:2207–2224

    Article  PubMed  CAS  Google Scholar 

  • Araake M, Hara T, Watabe H, Nishino T (2002) In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone. Jpn J Antibiot 55:778–790

    PubMed  CAS  Google Scholar 

  • Axten JM, Brooks G, Brown P et al (2004) PCT Int Appl WO004058144

    Google Scholar 

  • Bax BD, Chan PF, Eggleston DS et al (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940

    Article  PubMed  Google Scholar 

  • Black MT, Coleman K (2009) New inhibitors of bacterial topoisomerase GyrA/ParC subunits. Curr Opin Investig Drugs 10:804–810

    PubMed  CAS  Google Scholar 

  • Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C (2008) Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 52:3339–3349

    Article  PubMed  CAS  Google Scholar 

  • Bradbury BJ, Pucci MJ (2008) Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 8:574–581

    Article  PubMed  CAS  Google Scholar 

  • Cambau E, Matrat S, Pan XS, Bettoni RRD, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM (2009) Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 63:443–450

    Article  PubMed  CAS  Google Scholar 

  • Charifson PS, Grillot AL, Grossman TH et al (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51:5243–5263

    Article  PubMed  CAS  Google Scholar 

  • Chu DT, Fernandes PB, Claiborne AK, Shen L, Pernet AG (1988) Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp Clin Res 14:379–383

    PubMed  CAS  Google Scholar 

  • Chung DT, Tsai TY, Chen SJ et al (2009) Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54:411–417

    Article  PubMed  Google Scholar 

  • Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–497

    Article  PubMed  CAS  Google Scholar 

  • Covington P, Davenport JM, Andrae D, O’Riordan W, Liverman L, McIntyre G, Almenoff J (2011) Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55:5790–5797

    Article  PubMed  CAS  Google Scholar 

  • Domogala JM, Hagen SE (2003) Structure-activity relationships of the quinolone antibacterials in the new millennium: some things change and some do not. In: Hooper DC, Rubenstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, DC

    Google Scholar 

  • Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2000) Quinolones action and resistance updated. Curr Top Med Chem 9:981–998

    Article  Google Scholar 

  • Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52:385–392

    Article  PubMed  CAS  Google Scholar 

  • Eakin AE, Green O, Hales N et al (2012) Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob Agents Chemother 56:1240–1246

    Article  PubMed  CAS  Google Scholar 

  • East SP, White CB, Barker O et al (2009) DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity. Bioor Med Chem Lett 19:894–899

    Article  CAS  Google Scholar 

  • Ellsworth EL, Tran TP, Showalter HDH et al (2006) 3-Aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. J Med Chem 49:6435–6438

    Article  PubMed  CAS  Google Scholar 

  • Emmerson AM, Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51(Suppl S1):13–20

    Google Scholar 

  • Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P (2010) Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations. J Antimicrob Chemother 65:2530–2533

    Article  PubMed  CAS  Google Scholar 

  • Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM, Lynch AS (2011) Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob Agents Chemother 55:5522–5528

    Article  PubMed  CAS  Google Scholar 

  • Fritsche TR, Biedenbach DJ, Jones RN (2009) Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea. Antimicrob Agents Chemother 53:1221–1224

    Article  PubMed  CAS  Google Scholar 

  • Giannarini G, Tascini C, Selli C (2009) Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol 4:13–24

    Article  PubMed  CAS  Google Scholar 

  • Grossman TH, Bartels DJ, Mullin S (2007) Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 5:657–666

    Google Scholar 

  • Haas W, Pillar CM, Zurenko GM, Lee JC, Brunner LS, Morris TW (2009) Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 53:3552–3560

    Article  PubMed  CAS  Google Scholar 

  • Heide L (2009) Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol Adv 27:1006–1014

    Article  PubMed  CAS  Google Scholar 

  • Higgins PG, Stubbings W, Wisplinghoff H, Seifert H (2010) Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1613–1615

    Article  PubMed  CAS  Google Scholar 

  • Hoshino K, Inoue K, Murakami Y, Kurosaka Y, Namba K, Kashimoto Y, Uoyama S, Okumura R, Higuchi S, Otani T (2008) In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 52:65–70

    Article  PubMed  CAS  Google Scholar 

  • Huband MD, Cohen MA, Zurack M et al (2007) In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191–1201

    Article  PubMed  CAS  Google Scholar 

  • Jones RN, Fritsche TR, Sader HS (2008) Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob Agents Chemother 52:3763–3775

    Article  PubMed  CAS  Google Scholar 

  • Keam SJ, Perry CM (2004) Prulifloxacin. Drugs 64:2221–2234

    Article  CAS  Google Scholar 

  • Kim EJ, Shin WH, Kim KS, Han SS (2004) Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem Toxicol 27:295–307

    Article  PubMed  CAS  Google Scholar 

  • Kuramoto Y, Ohshita Y, Yoshida J, Yazaki A, Shiro M, Koike T (2003) A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group. J Med Chem 46:1905–1917

    Article  PubMed  CAS  Google Scholar 

  • Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC (2006) In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother 56:684–688

    Article  Google Scholar 

  • Lawrence L, Benedict M, Hart J, Hawkins A, Li D, Medlock M, Hopkins S, Burak E (2011) Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr A2-045a

    Google Scholar 

  • Lesher GY, Froelic EJ, Gruett MD, Bailey JH, Brundage RP (1962) 1,8-Naphthyridine derivatives. A new class of therapeutic agents. J Med Chem 91:1063–1065

    Article  CAS  Google Scholar 

  • Levasseur, P, Delachaume C, Lowther J, Hodgson J (2005) Minimum inhibitory concentrations (MIC) and mutation prevention concentrations (MPC) of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains. In: 45th interscience conference on antimicrobial agents and chemotherapy, abstr F-507

    Google Scholar 

  • Levasseur, P, Girard AM, Lowther J (2007) Efficacy of oral NXL101, a novel topoisomerase inhibitor, against fluoroquinolone-susceptible (FQS) and -resistant (FQR) Streptococcus pneumoniae (Sp) strains in a mouse pneumonia model. In: 47th interscience conference on antimicrobial agents and chemotherapy, abstr F1-2125

    Google Scholar 

  • Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA (2010) Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54:405–410

    Article  PubMed  CAS  Google Scholar 

  • Lowther J, Levasseur P, Girard AM, Delachaume C, Borgonovi M, Hodgson J (2006) Efficacy of NXL101, a novel topoisomerase inhibitor, against multi-resistant Staphylococcus aureus in murine septicaemia and thigh muscle infections. In: 46th interscience conference on antimicrobial agents and chemotherapy, abstr F1-1999

    Google Scholar 

  • Mani N, Gross CH et al (2006) In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 50:1228–1237

    Article  PubMed  CAS  Google Scholar 

  • Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19(Suppl 1):20–29

    Article  PubMed  CAS  Google Scholar 

  • Mitscher LA (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 105:559–592

    Article  PubMed  CAS  Google Scholar 

  • Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K (2010) In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 54:1955–1964

    Article  PubMed  CAS  Google Scholar 

  • Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS (2011) Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother 55:5512–5521

    Article  PubMed  CAS  Google Scholar 

  • Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK (2003) In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 47:3260–3269

    Article  PubMed  CAS  Google Scholar 

  • Oppegard LM, Hamann BL, Streck KR, Ellis KC, Fiedler HP, Khodursky AB, Hiasa H (2009) In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother 53:2110–2119

    Article  PubMed  CAS  Google Scholar 

  • Owens RC Jr, Ambrose PG (2000) Clinical use of the fluoroquinolones. Med Clin North Am 84:1447–1469

    Article  PubMed  CAS  Google Scholar 

  • Owens RC Jr, Ambrose PG (2005) Antimicrobial safety: focus on quinolones. Clin Infect Dis 41(Suppl 2):S144–S157

    Article  PubMed  CAS  Google Scholar 

  • Pan XS, Gould KA, Fisher LM (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother 53:3822–3831

    Article  PubMed  CAS  Google Scholar 

  • Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH (2006) In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 50:2261–2264

    Article  PubMed  CAS  Google Scholar 

  • Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA Jr, Bradbury BJ, Deshpande M (2007) In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant Gram-positive pathogens. Antimicrob Agents Chemother 51:1259–1267

    Article  PubMed  CAS  Google Scholar 

  • Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M (2011) In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother 55:2860–2871

    Article  PubMed  CAS  Google Scholar 

  • Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME (2011) Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents 37:283–290

    Article  PubMed  CAS  Google Scholar 

  • Reck F, Alm R, Brassil P et al (2011) Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J Med Chem 54:7834–7847

    Article  PubMed  CAS  Google Scholar 

  • Rubenstein E (2001) History of quinolones and their side effects. Chemother 47(Suppl 3):3–8

    Article  Google Scholar 

  • Ryder NS (2010) Discontinued drugs in 2008: anti-infectives. Expert Opin Investig Drugs 19:1–21

    Article  PubMed  CAS  Google Scholar 

  • Sherer BA et al (2011) Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorg Med Chem Lett 21:7416–7420

    Article  PubMed  CAS  Google Scholar 

  • Tari LW, Bensen D, Tzross M et al (2011a) The discovery of potent, dual targeting pyrrolopyrimidine inhibitors of bacterial DNA gyrase B and topoisomerase IV with broad spectrum antibacterial activity. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr F1-1837

    Google Scholar 

  • Tari LW, Bensen D, Tzross M et al (2011b) The discovery of novel, dual targeting inhibitors of bacterial DNA gyrase B and topoisomerase IV using pharmacophore-based crystallographic fragment screening. In: 51st interscience conference on antimicrobial agents and chemotherapy, abstr F2-1872

    Google Scholar 

  • Tarral A, Rangaraju M, Merdjan H, Girard AM, Delachaume C, Lowther J (2007) Plasma bactericidal activity of NXL101 in healthy volunteers after single intravenous administration of 50 to 700 mg. In: 47th interscience conference on antimicrobial agents and chemotherapy, abstr A808

    Google Scholar 

  • Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock T (2009) Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 25:1159–1169

    Article  PubMed  CAS  Google Scholar 

  • Wang Q, Lucien E, Hashimoto A et al (2007) Isothiazoloquinolones with enhanced antistaphylococcal activities against multi-drug resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J Med Chem 50:199–210

    Article  PubMed  CAS  Google Scholar 

  • Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 65:520–524

    Article  PubMed  CAS  Google Scholar 

  • Wiles JA, Bradbury BJ, Pucci MJ (2010) New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Patents 20:1295–1319

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Achillion Pharmaceuticals, 300 George Street, New Haven, CT, 06511, USA

    Michael J. Pucci & Jason A. Wiles

Authors
  1. Michael J. Pucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason A. Wiles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Pucci .

Editor information

Editors and Affiliations

  1. Dipartimento di Biotecnologie e Scienze Molecolari, Università degli Studi dell'Insubria, Varese, Italy

    Flavia Marinelli

  2. Parque Tecnológico Ciencias de la Salud, Fundación MEDINA, Granada, Spain

    Olga Genilloud

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pucci, M.J., Wiles, J.A. (2014). Bacterial Topoisomerase Inhibitors: Quinolones and Beyond. In: Marinelli, F., Genilloud, O. (eds) Antimicrobials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39968-8_16

Download citation

Publish with us

Policies and ethics

Search

Navigation